Epidemiology and outcome of infections with carbapenem-resistant Gram-negative bacteria treated with polymyxin B-based combination therapy

Risk Factors for Treatment Failure of Polymyxin B Monotherapy for Carbapenem-Resistant Klebsiella pneumoniae Infections

(2013) Yanina Dubrovskaya et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Colistin and Rifampicin Compared With Colistin Alone for the Treatment of Serious Infections Due to Extensively Drug-Resistant Acinetobacter baumannii: A Multicenter, Randomized Clinical Trial

(2013) Emanuele Durante-Mangoni et al.   CLINICAL INFECTIOUS DISEASES

Population Pharmacokinetics of Intravenous Polymyxin B in Critically Ill Patients: Implications for Selection of Dosage Regimens

(2013) Ana M. Sandri et al.   CLINICAL INFECTIOUS DISEASES

Higher Incidence of Acute Kidney Injury With Intravenous Colistimethate Sodium Compared With Polymyxin B in Critically Ill Patients at a Tertiary Care Medical Center

(2013) Darowan S. Akajagbor et al.   CLINICAL INFECTIOUS DISEASES

“Swimming in resistance”: Co-colonization with carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii or Pseudomonas aeruginosa

(2012) Dror Marchaim et al.   AMERICAN JOURNAL OF INFECTION CONTROL

Treatment Outcome of Bacteremia Due to KPC-Producing Klebsiella pneumoniae: Superiority of Combination Antimicrobial Regimens

(2012) Zubair A. Qureshi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Association Between Colistin Dose and Microbiologic Outcomes in Patients With Multidrug-Resistant Gram-Negative Bacteremia

(2012) Giulia Vicari et al.   CLINICAL INFECTIOUS DISEASES

"Silent" Dissemination of Klebsiella pneumoniae Isolates Bearing K. pneumoniae Carbapenemase in a Long-term Care Facility for Children and Young Adults in Northeast Ohio

(2012) R. A. Viau et al.   CLINICAL INFECTIOUS DISEASES

Predictors of Mortality in Bloodstream Infections Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae: Importance of Combination Therapy

(2012) M. Tumbarello et al.   CLINICAL INFECTIOUS DISEASES

Pharmacokinetics and pharmacodynamics of ‘old’ polymyxins: what is new?

(2012) Phillip J. Bergen et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies

(2012) Y. Cai et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy

(2012) Christine J. Kubin et al.   JOURNAL OF INFECTION

Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically Ill Patients from a Multicenter Study Provide Dosing Suggestions for Various Categories of Patients

(2011) S. M. Garonzik et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment

(2011) O. Zarkotou et al.   CLINICAL MICROBIOLOGY AND INFECTION

Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09)

(2011) A. C. Gales et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Activity of Polymyxin B and the Novel Polymyxin Analogue CB-182,804 Against Contemporary Gram-Negative Pathogens in New York City

(2011) John Quale et al.   Microbial Drug Resistance

Polymyxin B versus other antimicrobials for the treatment of Pseudomonas aeruginosa bacteraemia

(2010) C. H. Kvitko et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In Vitro Evaluation of Antibiotic Synergy for Polymyxin B-Resistant Carbapenemase-Producing Klebsiella pneumoniae

(2010) A. Elemam et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Cluster of bloodstream infections caused by KPC-2 carbapenemase-producing Klebsiella pneumoniae in Manhattan

(2009) Abhijeet S. Nadkarni et al.   AMERICAN JOURNAL OF INFECTION CONTROL

Does the Activity of the Combination of Imipenem and Colistin In Vitro Exceed the Problem of Resistance in Metallo- -Lactamase-Producing Klebsiella pneumoniae Isolates?

(2009) M. Souli et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Activity of NXL104 in Combination with  -Lactams against Klebsiella pneumoniae Isolates Producing KPC Carbapenemases

(2009) A. Endimiani et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical and Economic Consequences of Ventilator‐Associated Pneumonia

(2009) Alpesh Amin   CLINICAL INFECTIOUS DISEASES

Multidrug-resistantPseudomonas aeruginosaandAcinetobacter baumannii: resistance mechanisms and implications for therapy

(2009) Alexandre P Zavascki et al.   Expert Review of Anti-Infective Therapy

In vitro activity of the  -lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases

(2009) T. Stachyra et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Continuous versus intermittent infusion of polymyxin B in the treatment of infections caused by multidrug-resistant Gram-negative bacteria

(2007) Christine B. Teng et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS